StreetInsider.com News Articles

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7

Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion

Thu, 27 Aug 2026 07:02:00 -0400

Highlights:

Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%;
Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion, representing a year-on-year increase of 17%;
Global operational capabilities continued to improve, with overseas revenue reaching RMB49.16 billion, representing a year-on-year increase of 5.3% and accounting for 56.5% of the Group's total revenue;
Investment in technology innovation reached RMB4.2 billion, representing a year-on-year increase of 16.7%. Innovative drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7